GLP-1 FDA Safety Alerts: 2026 Tracker and Drug/Lot Checker

Editorial disclosure: The RX Index earns money from some services linked elsewhere on this site. No company can pay to appear in this tracker, to stay out of it, or to change how an alert is classified. There are no paid provider links in the tracker or in any safety section on this page.

Last verified: August 5, 2026 · Dataset version 1.0 · By Kaden Coziar, Founder & Managing Editor · The RX Index Research

The short version

Here is the plain-English summary of the current GLP-1 FDA safety alerts: the FDA sources we reviewed through August 5, 2026 do not show one blanket recall or stop-use order covering every GLP-1. They do show product-, company-, lot-, serial-, and handling-specific actions affecting both compounded products and some FDA-approved products. A warning letter is not a recall.

If an FDA notice says not to use something, the exact product, source, lot, serial number, or shipment condition controls the answer. If it says FDA is evaluating a possible signal, that is not a confirmed cause and not a stop-use order.

One more thing before you scroll. The biggest FDA action on these drugs in the last two years didn't add a warning. It took one away. We'll show you which one — and the FDA letter that landed 51 days later that almost nobody has connected to it.

This page is for you if

• You saw an FDA headline and want to know if it touches the medicine in your fridge
• Your telehealth company, pharmacy, compounder, or manufacturer got named in something
• Your package arrived warm, or the label looks off
• You have a lot number and no idea what to do with it
• You're supposed to inject tonight and you're not sure you should

This page cannot

• Tell you your product is safe
• Diagnose your symptoms
• Prove a side effect was caused by the drug
• Replace your prescriber or pharmacist

If you are having severe or fast-worsening symptoms right now, stop reading and get medical care. A web page is the wrong tool for that.

What we actually verified

We opened FDA's own records and read them. Specifically: FDA's Drug Alerts and Statements index, FDA's page on unapproved GLP-1 drugs, FDA's compounding-policy statement, the Drug Safety Communication on suicidal ideation, individual warning letters, official manufacturer recall notices, and recall records in FDA's Enforcement Report system and openFDA enforcement dataset.

Every row below separates five things:

1. What FDA or the recalling firm actually identified
2. The exact product, source, lot, or condition involved
3. What the reader should do
4. What the record does not establish
5. The primary source you can open yourself

We did not test any product. We did not contact any manufacturer. No clinician reviewed this page. It is an editorial research page, not medical advice.

Start here: match what you saw to what it actually is

→ Check whether an alert applies to my medication Match your drug, your source, your lot, and your shipment against the current records below.

What are the current GLP-1 FDA safety alerts?

Answer capsule: The FDA sources reviewed through August 5, 2026 do not show a class-wide GLP-1 recall or stop-use order. This tracker separates the records into seven practical groups: do-not-use actions, products to match before the next dose, FDA-approved product recalls, signals under evaluation, closed reviews, company actions that are not patient recalls, and policy or access updates.

Here's the thing nobody tells you: the word "alert" is doing a lot of different jobs.

A counterfeit Ozempic notice can sit on one rolling page. A compounding policy update can sit on another. A sterile-product recall may only appear in an Enforcement Report or inside a warning letter filed under the compounder's name. A possible safety signal appears in a quarterly adverse-event table. A company can receive a warning letter without any patient product being recalled.

FDA's records are accurate. They're just scattered across systems, filed under names you would not always think to search.

So we pulled the patient-action layer into one place.

The RX Index GLP-1 FDA Alert Classification & Action Tracker

Sorted by what the record asks you to do — not by whichever date makes the headline look newest.

Group 1 — FDA says do not use this product or shipment

Group 2 — Match your product before your next dose

Group 3 — Product-specific recalls of FDA-approved GLP-1 products

Group 4 — FDA is still evaluating

Group 5 — Reviews FDA has closed

Group 6 — Company actions that are not patient recalls

Group 7 — Policy and access, not safety

One number almost nobody has read. In the April 1, 2026 statement, FDA said that, at that time, it did not intend to take action against a compounder for regularly or inordinately compounding an "essentially a copy" product if the compounder filled four or fewer prescriptions of that compounded drug product in a calendar month. FDA also gave a B12 example: it may treat a compounded semaglutide-plus-B12 product as essentially a copy when the products use the same route and both ingredient strengths are within 10% of the corresponding commercially available products.

That is an enforcement position inside a larger legal framework, not a universal permission slip and not a patient-safety score.

→ Match my product, lot, or pharmacy Use the guided checker when FDA's wording does not look exactly like your label.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. A general answer can't resolve those for you. Once you've settled whether a safety action applies, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

What this tracker can't tell you

Let's be straight about the limit, because it changes how you should read everything above.

We cannot tell you your product is safe. If your lot doesn't appear in any FDA record, that means this tracker did not find a published action matching it — not that the vial or pen in your hand is fine. Quality problems can exist before a public action appears. That's how recalls happen.

If what you want is someone to inspect your medicine and certify it, that's your pharmacist, manufacturer, and prescriber. They can examine your actual product and dispensing record. We can't.

But because we're not pretending to certify anything, we can do the thing that's actually useful: every tracker row traces to a primary record you can open yourself. No scores we invented. No "critical" or "moderate" labels dressed up as FDA findings. Just what the record says, when, about what, and what action follows.

That's the trade. We give up the reassurance you came for. You get information you can check.

Does this FDA alert affect the GLP-1 I'm taking? {#checker}

Answer capsule: Whether an FDA alert affects you depends on more than the drug name. The answer changes based on whether you have an FDA-approved brand or generic product, a pharmacy-compounded product, a counterfeit or fraudulently labeled product, which firm made or dispensed it, the exact lot and serial number, and whether the shipment stayed within labeled storage conditions.

Find these five things first

Go get your box, vial, pen, bottle, or dispensing paperwork. You need:

1. The exact name — brand name, generic name, or ingredient if compounded
2. The form and strength — pen, vial, tablet; and the concentration if it is a vial
3. Who made and dispensed it — manufacturer, compounding pharmacy, outsourcing facility, and telehealth company when relevant
4. The lot number, NDC, and serial number if one appears
5. How it arrived — cold, cool, warm, damaged, or outside the stated storage conditions

Number three trips people up. Your telehealth company, prescriber, dispensing pharmacy, and the facility that made or repackaged the product can be different businesses. A warning letter to one does not automatically establish a recall involving the others. Check each named entity.

Which kind of product do you have?

Do not use the phrase "legally compounded" as a visual category you can identify from a vial. The legality of a compounded product depends on the prescription, patient-specific need, ingredient, facility, timing, sourcing, and compliance facts. A label alone cannot settle it.

What the checker gives you

Four possible answers, and we say which one you got:

• Exact match found — the action, date, scope, source, and next step
• Possible match — the one missing detail needed to resolve it
• No match found — no action in this tracker matches the information entered
• Can't verify — the available details do not identify the product or source

A "no match" result must say this exactly:

No matching FDA action was found in the current tracker. This is not a safety certification. Confirm anything unresolved about your product, dose, storage, or symptoms with the dispensing pharmacy or your prescriber.

The checker must never calculate a dose, diagnose a symptom, claim a product is safe, or tell someone to continue injecting because no match appeared.

→ Check my exact product Free. No email. No account. Match the identifiers before you react to the headline.

Should I stop taking my GLP-1 because of an FDA warning?

Answer capsule: Do not stop or change a prescribed GLP-1 just because a headline uses the word "warning." Follow the instruction attached to the exact action. FDA has issued direct stop-use instructions for matching counterfeit Ozempic, products from Fullerton Wellness, and injectable GLP-1 shipments that arrive warm; recall instructions depend on the exact product and lot.

The situations where the record tells you not to use it

Do not use the product when:

• It matches FDA's exact counterfeit description
• It came from Fullerton Wellness within the scope of FDA's stop-use communication
• It is an injectable GLP-1 shipment that arrived warm or with insufficient refrigeration
• The recalling firm, pharmacy, or manufacturer tells you your exact product and lot are included and instructs you not to use it
• FDA or another competent regulator issues a direct product-specific stop-use instruction

That list is deliberately written as categories, not as a claim that the current tracker can never miss a new notice. A recall database changes. Your exact lot and the current source control the answer.

When to call before your next dose

Call the pharmacy, manufacturer, or prescriber first if:

• Your concentration changed from your last vial
• The syringe instructions look different
• You cannot verify the pharmacy or manufacturer on the label
• The label says semaglutide sodium or semaglutide acetate
• Your lot number cannot be matched to the recall scope
• The packaging arrived damaged
• The medicine looks cloudy, discolored, or has particles when the labeling says it should not
• The alert names your source but you cannot tell whether your specific product or dispense date is included

None of that proves a defect. It means you have a question the dispensing source or a licensed professional should resolve before use.

When FDA says keep going

The clearest example is the January 2026 suicidality review. FDA found no increased risk and told patients to continue taking medication as prescribed while discussing concerns and mood changes with a healthcare professional.

That's an FDA action that made the labeling less alarming. It's also the one most likely to be described wrong by an old article that still treats the 2024 investigation as open.

When your symptoms matter more than this page

Say it plainly: a lookup result should never delay care. Severe or fast-worsening symptoms need direct medical evaluation. This tracker matches regulatory records to products. It does not evaluate you.

Has any GLP-1 been recalled?

Answer capsule: Yes. FDA records include product- and lot-specific Class II recalls involving FDA-approved Wegovy, FDA-approved generic liraglutide, and compounded or repackaged semaglutide and tirzepatide products. No verified recall in this tracker covers the entire GLP-1 class or every product containing one ingredient.

Here's the part many pages in this space leave out, and we're going to say it directly: FDA-approved GLP-1 products have been recalled too.

That does not erase the difference between FDA-approved and compounded drugs. It shows why the exact recall reason and scope matter more than a category slogan.

The verified FDA-approved product recalls in this tracker involved:

• A Wegovy distribution temperature excursion affecting one lot and 48 cartons
• A later four-lot Wegovy recall after hair was found in two pens during inspection; Novo Nordisk said those two pens never reached retail or patients and recommended no patient action
• A Lupin generic liraglutide recall for particulate matter in a cartridge

The compounded and repackaged-product actions involved different patterns:

• Lack of sterility assurance
• Microbial contamination risk
• Failed sterility testing
• Potency results below labeled strength
• Broad recalls of within-expiry sterile products from named facilities

That contrast is the actual finding. Both approved and non-approved products can be recalled. The approval status, reason, lot, source, and instruction tell you what the recall means.

Why FDA's ordinary recall page isn't enough

FDA says not every recall receives a public press release or appears as a posted company announcement. The agency's Enforcement Reports and openFDA enforcement dataset contain recall records that do not have a standalone consumer news page.

So if you search the news and find nothing, that proves nothing. Search the recall database by product, NDC, firm, and lot.

How to check your own lot

1. Find the lot number on the carton and product itself
2. Record the NDC, strength, dosage form, expiration date, manufacturer, and dispensing pharmacy
3. Search FDA's Drug Recalls and Enforcement Report system by product or firm
4. If compounded or repackaged, search the compounder, outsourcing facility, and dispensing pharmacy separately
5. Read the product description carefully; recalls are often limited by strength, packaging, lot, dispense date, or expiration status
6. If the record is unclear, call the dispensing pharmacy or manufacturer and ask it to match your dispensing record

Which Ozempic lots has FDA identified as counterfeit?

Answer capsule: FDA's U.S. counterfeit Ozempic page contains notices involving lot NAR0074 with serial 430834149057, lot PAR0362 with serial numbers beginning 51746517, and lot PAR1229 identified by the placement of the EXP/LOT text. The lot number alone is not enough for the two newer notices.

The identifying burden changed

Look at those three notices in order.

December 2023: FDA gave a lot and one exact serial number.

April 2025: FDA gave an authentic lot number plus a counterfeit serial-number prefix.

December 2025: FDA again used an authentic lot number, but the consumer-facing tell was the position of the EXP/LOT text on the label.

The verified conclusion is not that the 2023 lot was fake or that there is a neat security progression. FDA's 2023 notice does not establish that. The conclusion is narrower and more useful: a lot number by itself is no longer enough to resolve the two newer notices. You need the serial or label configuration too.

One more wrinkle on PAR1229 specifically. It is an authentic Novo Nordisk lot. Real Ozempic carries it. FDA also says Patient Assistance Program product with that lot may be authentic. So "I have PAR1229" is not the answer. It is the reason to inspect the label placement and source.

→ Check my Ozempic lot and label Enter every identifier FDA published, not just the lot.

What is the FDA warning about compounded semaglutide and tirzepatide?

Answer capsule: FDA has not issued one warning meaning all compounded semaglutide or tirzepatide is recalled. Its current concerns include dosing errors, salt forms that are different active ingredients, improper refrigeration during shipping, fraudulent pharmacy information on labels, illegal online sales, products sold as "research use only," adverse-event reports, and facility-specific sterility or potency actions.

Let's define the terms once, then use them freely.

Compounded means a licensed pharmacy, physician, or registered outsourcing facility prepared a drug product under a compounding pathway rather than a manufacturer marketing a finished drug under an FDA-approved application. A 503A compounder generally works from patient-specific prescriptions and must satisfy the conditions of section 503A to receive its exemptions. A 503B outsourcing facility registers with FDA, can compound batches under section 503B, and must satisfy the conditions and manufacturing requirements that apply to it.

Neither category makes the finished compounded product FDA-approved. A compounded drug is also not an FDA-approved generic. FDA reviews a generic drug before marketing; it does not preapprove a compounded finished product for safety, effectiveness, and quality.

Compounding can meet a real patient need. FDA says compounded drugs should be used when a patient's medical needs cannot be met by an available FDA-approved drug. That is not the same as saying every compounded product is unlawful or every compounded product is safe.

FDA's specific concerns

1. Dosing errors. FDA received reports of patients administering five to 20 times the intended compounded semaglutide dose, and reports involving clinician miscalculations of five to 10 times the intended dose. Some patients needed medical attention or hospitalization. The repeated failure point was not one magic number. It was conversion among milligrams, milliliters, concentrations, and syringe units.

If the concentration changes between vials, the injection volume can change even when the prescribed milligram dose does not. Confirm all four values with the prescriber or compounder. This page will not calculate an injection dose.

2. Salt forms. FDA says semaglutide sodium and semaglutide acetate are different active ingredients from the active ingredient in approved semaglutide drugs. FDA says it does not have information showing the same chemical and pharmacologic properties and is not aware of a lawful basis for their use in compounding.

3. Warm shipments. FDA says injectable GLP-1 drugs require refrigeration as indicated in their package inserts and recommends not using an injectable GLP-1 that arrives warm or with insufficient refrigeration.

4. Fraudulent labels. FDA has found labels naming pharmacies that do not exist and labels naming licensed pharmacies that did not compound the product.

5. Ingredients FDA says cannot be used in compounding. FDA's current concerns page states that retatrutide and cagrilintide cannot be used in compounding under federal law, are not components of FDA-approved drugs, and have not been found safe and effective for any condition.

6. Illegal online sales and research-use disclaimers. FDA has warned sellers offering semaglutide, tirzepatide, or retatrutide as "for research purposes" or "not for human consumption" while selling directly to consumers for human use with dosing instructions.

7. Doses beyond approved labeling. FDA says it has received reports that may relate to compounded semaglutide or tirzepatide prescribed in larger individual doses, more frequent schedules, or faster titration than the approved-drug labels describe.

About the adverse-event numbers

FDA published these figures as of May 31, 2026:

• 990 adverse-event reports associated with compounded semaglutide
• More than 730 associated with compounded tirzepatide

Two things to know before you use those numbers — or trust someone else who does.

First, FDA says state-licensed pharmacies that are not outsourcing facilities generally are not federally required to report adverse events to FDA, so compounded-product events are likely underreported.

Second, a report count is not an incidence rate and is not proof of cause. FDA says it is not always possible to determine whether the drug directly caused the event or whether other factors contributed.

Anyone handing you a GLP-1 adverse-event number without the ingredient, data cutoff, reporting limitations, and denominator is handing you a decoration, not a risk estimate.

For deeper methodology, see our compounded GLP-1 enforcement tracker and the dedicated adverse-event research asset when live.

Verify your compounded product before your next dose {#checklist}

Work through this in order:

1. The prescriber. Is the prescriber licensed? Did a real clinical evaluation occur? Can you reach a licensed clinician after delivery?
2. The dispensing pharmacy. Search the state board of pharmacy for the name on the label. Call using contact information you found independently. Ask whether it dispensed or compounded your exact product and lot.
3. The facility. If a separate outsourcing facility or manufacturer appears, verify that entity too.
4. The ingredient. Semaglutide or tirzepatide? What exact form? What else is included?
5. The numbers. Dose in mg, concentration in mg/mL, volume in mL, and syringe marking. All four.
6. The package. Lot, expiration, NDC when applicable, damage, missing instructions, spelling errors, or an address that does not match the licensed entity.
7. The temperature. Did the product arrive within its labeled shipping and storage conditions?
8. Photograph everything before discarding the label, shipping material, syringe instructions, or outer carton.

One caution: a product that looks normal is not verified. You cannot see sterility. Clear liquid in an intact vial does not tell you whether it was made, stored, or labeled correctly.

→ Print or save this GLP-1 Product Verification Checklist Use your browser’s print or save-to-PDF function. Keep the lot, source, dose fields, and pharmacy answers together.

What's the difference between an FDA safety alert, a recall, a warning letter, a label change, and a safety signal?

Answer capsule: These are different actions with different meanings. A recall removes or corrects defined product, a warning letter describes alleged regulatory violations, a possible safety signal triggers evaluation, and a labeling decision can add, change, or remove information without recalling the drug.

If you only read one table on this page, make it this one. Most frightening GLP-1 headlines we checked came from treating two of these rows as the same thing.

And one more distinction that costs people real money: "FDA-registered" is not "FDA-approved." A facility may register with FDA. Registration does not mean FDA approved the facility's compounded products. FDA also says it does not approve or license compounding facilities. Any seller using "FDA-registered facility" to imply product approval is blurring categories FDA has explicitly told telehealth companies not to blur.

Did FDA remove the suicide warning from Wegovy and Zepbound?

Answer capsule: Yes. On January 13, 2026, FDA said its comprehensive review found no increased risk of suicidal ideation or behavior with GLP-1 receptor agonists and asked the application holders for Saxenda, Wegovy, and Zepbound to remove the warning from their labeling. FDA told patients to continue taking medication as prescribed and discuss concerns with a healthcare professional.

This surprises people, so let's be clear about the direction of travel: FDA investigated the question, did not identify increased risk, and asked for the warning to come off.

The review included a meta-analysis of 91 placebo-controlled trials covering 107,910 participants: 60,338 treated with a GLP-1 receptor agonist and 47,572 treated with placebo. FDA also conducted a Sentinel cohort study covering 2,243,138 new users, comparing GLP-1 receptor agonists with SGLT2 inhibitors in people with type 2 diabetes. FDA reported no increased risk in those analyses.

If you're reading a page that says FDA is still evaluating this question, that page is out of date unless it is explicitly describing the earlier 2024 stage of the review.

The part nobody has connected

Here's something we found by putting two FDA documents next to each other.

Fifty-one days after the January 13 de-warning, FDA dated a March 5, 2026 warning letter to Novo Nordisk concerning postmarketing adverse-drug-experience reporting. The letter describes, among other issues, a semaglutide suicide report that had not been submitted and a semaglutide suicidal-ideation case whose required review and reporting were delayed. FDA also objected to procedures that allowed reports to be rejected or canceled based on the reporter's causality opinion.

So: FDA cleared the suicidality question in January, then told a major manufacturer in March that its spontaneous-reporting procedures had serious failures.

The tempting read is "FDA cleared the drug using data the company failed to report." That read is not supported by the two documents.

The January conclusion rested on a 91-trial meta-analysis, a controlled Sentinel cohort study, and the broader evidence FDA described — not on spontaneous reports alone. The March letter shows why spontaneous-reporting systems have limits. It does not overturn FDA's January causal conclusion.

Two more things worth stating flatly. FDA's warning letter identified reporting failures; it did not conclude that semaglutide caused each underlying event. And nothing in the records supports calling this a "cover-up."

What you should still do

The label changed. Your judgment should not disappear. New or worsening depression, major mood changes, or thoughts of self-harm require prompt professional help. A population-level finding does not evaluate an individual person.

What GLP-1 risks is the FDA still evaluating?

Answer capsule: FDA listed NAION — non-arteritic anterior ischemic optic neuropathy — as a potential signal for the listed GLP-1 receptor agonists in its October–December 2024 AEMS table and said it was evaluating whether regulatory action was needed. That status does not establish causation, quantify a risk increase, or tell patients to stop treatment.

"Potential signal" is a specific status, and it's narrower than it sounds. It means FDA identified information worth evaluating. FDA's AEMS program says listing a drug does not mean FDA has determined that the drug has the risk, and it does not mean patients should stop while the evaluation is underway.

What to do with it:

• Sudden vision changes need prompt medical evaluation
• Do not turn a quarterly signal entry into a personal diagnosis
• Do not invent a risk multiplier FDA has not published in this action
• Discuss your own symptoms and risk factors with the prescriber
• Watch for a later FDA Drug Safety Communication or labeling action

What does not belong in this tracker: we did not create new "breaking alert" rows out of long-standing labeled risks such as pancreatitis, gallbladder disease, gastrointestinal effects, or thyroid-tumor warnings. Existing prescribing information matters, but a long-standing label warning is not a new FDA safety alert.

For the chronology of actual label changes, use the GLP-1 FDA label changes tracker.

Do FDA warning letters mean my provider's medication is unsafe?

Answer capsule: Not automatically. A warning letter can concern misleading marketing, obscured sourcing, unapproved-drug promotion, adverse-event reporting, insanitary manufacturing, or other violations. Marketing letters do not establish contamination; manufacturing letters can sit beside product recalls, which is why the exact letter and the recall database must be checked separately.

FDA announced 30 telehealth-company warning letters on March 3, 2026. It later published additional June 8 letters and a June 15 telehealth promotion page explaining the recurring violations.

Most of those telehealth letters were about what companies said and showed:

• Claims implying a compounded drug was the same as an FDA-approved product
• Claims calling a compounded product a generic
• Claims suggesting compounded products were FDA-approved or evaluated by FDA
• Telehealth-branded product images that could obscure which pharmacy or facility actually compounded the drug
• Claims implying FDA approved or licensed a pharmacy or outsourcing facility

Those are real problems. They're about whether the buyer was told the truth. They are not, by themselves, findings about a vial's sterility.

Manufacturing letters are different. New Life Pharma, ProRx, Boothwyn, GenoGenix, and Thrive involved manufacturing, sterility, potency, or repackaging issues and had product-removal actions connected to them. Those require product-level follow-up.

Your decision rule:

• Marketing letter only → do not stop medication solely because of the letter; verify who actually made the product and what claims were false
• Manufacturing letter plus recall → match the exact product, lot, expiration, and dispense date
• Direct FDA stop-use notice → follow the notice
• Adverse-event reporting letter → understand the reporting-system failure; do not convert it into an unsupported drug-causation claim

Check what happened after the letter

A warning letter is a dated snapshot. FDA's warning-letter database says later interaction can change the regulatory status of issues discussed in the letter. Search for:

• A company response when public
• A closeout letter
• A product recall
• A later inspection or warning
• Current facility registration or pharmacy-license status

A company named in an older letter may have corrected the problem. A company with no warning letter may simply not have been inspected or publicly cited. Absence of a warning letter is not a clean bill of health, and this site will not use it as one.

How do I report a GLP-1 side effect, dosing error, counterfeit, or quality problem?

Answer capsule: Patients and healthcare professionals can report adverse events, medication errors, and product-quality problems through FDA MedWatch online or by fax at 1-800-FDA-0178. A useful report includes the product, ingredient, strength, lot, serial, dispensing source, dose instructions, dates, shipment condition, photographs, symptoms, and medical care received.

Reporting matters more than most people think. The 990 and 730-plus compounded-product figures came from reports people and organizations submitted. FDA says compounded adverse events are likely underreported because many state-licensed pharmacies are not federally required to report them.

Save this before you report

• Product name and ingredient
• Form, strength, and concentration
• Lot, serial, and NDC when present
• Manufacturer, compounding facility, dispensing pharmacy, provider, and seller
• Prescription and dosing instructions
• Date received and date used
• Storage and shipping details
• Photographs of the label, packaging, product, and syringe instructions
• Symptoms and when they started
• Medical care received

What kind of report is it?

Different problems can be reported through the same safety system:

• Suspected adverse event
• Dosing or measurement error
• Suspected counterfeit
• Defective pen, vial, or syringe
• Damaged packaging
• Warm shipment
• Suspected contamination
• Mislabeling
• Pharmacy or manufacturer information that cannot be verified

Who else to tell

• Your prescriber — when symptoms, dose, or treatment decisions are involved
• The dispensing pharmacy — for lot verification, source records, and replacement
• The telehealth platform — when it sold or arranged the product
• Your state board of pharmacy — for licensing, dispensing, or label-fraud concerns
• The manufacturer — for an FDA-approved product; FDA's counterfeit Ozempic page lists Novo Nordisk customer care at 1-800-727-6500
• Emergency services — for urgent symptoms, first

→ Report a product problem to FDA MedWatch This goes to FDA. It is the most direct place to put a suspected side effect, dosing error, counterfeit, or quality problem into the federal safety system.

How can I check any FDA GLP-1 claim myself?

Answer capsule: Read the date attached to the specific FDA entry, check the page's current-as-of date, and search the system that actually owns the claim. Recalls belong in Enforcement Reports, warning letters in FDA's warning-letter database, labeling claims in current prescribing information, and possible signals in AEMS tables.

This is the skill that outlasts this page.

Step 1: Read the date on the entry, not just the page

FDA uses rolling pages that accumulate dated updates at one URL. The newest text may sit above older text that remains visible. Cite the date attached to the statement you are relying on.

Step 2: Check the page's current-as-of date

FDA's unapproved-GLP-1 concerns page has been updated after its original index date. A person citing only the first index date can miss later adverse-event counts, new fraudulent-label language, or updated handling guidance.

Step 3: Search the right database

• Recall: FDA Drug Recalls, Enforcement Reports, and openFDA enforcement data
• Warning letter: FDA warning-letter database plus any closeout
• Label: current FDA-approved prescribing information
• Potential signal: AEMS quarterly table plus later communications
• Compounding policy: the dated FDA policy entry and any later Federal Register final action

What this catches

FDA determined the semaglutide injection shortage was resolved on February 21, 2025. A tracker that reports February 2026 shifts the timeline by a full year and changes what the reader believes about shortage-dependent compounding.

It also catches category errors. Wegovy is semaglutide, not tirzepatide. A warning letter is not a recall. A proposal is not a final determination. An adverse-event report is not proof of cause.

Three checks taking a few minutes catch all four.

How we built and verified this tracker

Answer capsule: Each row was verified against the source type that establishes the claim: FDA drug alerts and safety communications, Enforcement Reports and openFDA recall records, warning letters, AEMS signal tables, current compounding guidance, Federal Register notices, and official manufacturer recall instructions. The tracker separates the action date from our verification date and records the exact scope.

Our source order

1. The FDA action, database record, or official regulatory notice itself
2. Current FDA-approved prescribing information for a labeling claim
3. An official manufacturer recall notice when it supplies lot-level patient instructions
4. State-board records for pharmacy-license verification
5. Peer-reviewed research for context, never to manufacture an FDA action
6. News coverage only to discover a record, never as the sole support for a tracker row

How we classify

Seven groups based on the reader action — not a severity score we invented:

1. Do not use
2. Match product before use
3. Product-specific FDA-approved recalls
4. Under evaluation
5. Closed review or labeling decision
6. Company action that is not a patient recall
7. Policy or access, not safety

We deliberately do not publish "critical / high / moderate" ratings. Those look like official findings and are not. If FDA says do not use it, we say do not use it. If FDA says it is evaluating, we say it is evaluating. If a manufacturer says no patient action is recommended, we do not rewrite that into "stop now."

What we exclude

Lawsuit allegations. Social-media anecdotes. Provider marketing claims. Manufacturer promotional material. Long-standing labeled side effects with no new FDA action. A single adverse-event report treated as proof of cause. State-only disciplinary actions until that layer can be built completely.

Limits you should know about

• FDA's public recall announcement page is not a complete list of all recalls
• openFDA says its records should not be used alone for medical decisions and may lag the live system
• No match is not a safety certification
• Warning-letter status can change
• A report does not prove causation
• A quality problem can exist before a public action appears
• We are not clinicians and this page has not been clinically reviewed

Change log and data

Every substantive update should record:

• Date changed
• Row changed
• Previous status or wording
• New status or wording
• New primary source
• Person who performed the verification

Rows should be archived rather than silently deleted.

Frequently asked questions about GLP-1 FDA warnings

Answer capsule: The most common mistakes are treating every FDA action as a recall, treating every recall as class-wide, or treating an adverse-event report as confirmed harm. These answers resolve the remaining product, compounding, counterfeit, warning-letter, and reporting questions.

Did FDA recall all GLP-1 drugs?

No. The FDA records verified for this page through August 5, 2026 show product-, firm-, strength-, and lot-specific recalls — not one recall covering every GLP-1 or every product containing semaglutide, tirzepatide, or liraglutide.

Did FDA ban compounded semaglutide?

No single word captures the current rules. Shortage-based enforcement periods ended, section 503A and 503B conditions still matter, and FDA's May 2026 503B Bulks List action was a proposal, not a final determination as of this verification. See Is compounded GLP-1 still available? and the post-shortage compounding rules for the full legal and access analysis.

Is a warning letter the same as a recall?

No. A warning letter describes FDA's findings about alleged violations and asks the recipient to correct them. A recall removes or corrects defined product. Some manufacturing letters sit beside recalls; many marketing letters do not.

Does an adverse-event report prove the GLP-1 caused the problem?

No. FDA says it is not always possible to determine whether the drug directly caused the reported event or whether other factors contributed.

Should I use a GLP-1 injection that arrived warm?

FDA recommends not using an injectable GLP-1 that arrives warm or with insufficient refrigeration. Contact the dispensing source for instructions and replacement.

Is every Ozempic pen with lot PAR1229 counterfeit?

No. PAR1229 is also an authentic Novo Nordisk lot. FDA identified the counterfeit configuration by the position of the EXP/LOT text and noted that Patient Assistance Program product with the lot may be authentic.

Is every Ozempic pen with lot PAR0362 counterfeit?

No. FDA's April 2025 notice pairs lot PAR0362 with serial numbers beginning 51746517. Check both.

Did FDA confirm GLP-1 drugs cause NAION?

No. FDA listed NAION as a potential signal and said it was evaluating whether regulatory action was needed. That status does not establish causation or a risk multiplier.

Does FDA still warn that GLP-1 drugs increase suicidal thoughts?

FDA's January 13, 2026 review found no increased risk and requested removal of the suicidal ideation and behavior warning from Saxenda, Wegovy, and Zepbound labeling. New or worsening mood symptoms still require professional attention.

How can I verify my compounding pharmacy?

Search the appropriate state board of pharmacy for the name and address on the label. Then contact the pharmacy through independently located information and ask whether it compounded or dispensed the exact product and lot.

What's the difference between compounded and generic?

A generic drug goes through FDA review before marketing under an approved application. A compounded product does not go through that finished-drug approval process. They are different regulatory categories and should never be described as interchangeable.

Can I tell if my vial is contaminated by looking at it?

No. Visible particles, cloudiness, damage, or discoloration can be reasons to stop and call the pharmacy, but normal appearance cannot verify sterility.

Does "FDA-registered facility" mean FDA approved the product?

No. Registration is not product approval. FDA also says it does not approve or license compounding pharmacies or outsourcing facilities.

How often is this tracker updated?

FDA alerts and recalls should be monitored daily, warning letters weekly, AEMS tables quarterly, compounding policy monthly, and every row rechecked whenever a new source changes its scope or status. The visible verification date must only change after the sources are actually rechecked.

Once you know where you stand

Answer capsule: Resolve the safety action first. Then decide whether you want an FDA-approved or compounded treatment path, whether insurance matters, which treatment form you prefer, and what monthly cost you can sustain. Those are provider-choice questions, not reasons to distort an FDA alert.

If you worked through this page and landed on "I want medicine I can trace through an approved manufacturer, NDC, lot, and public recall system," you are describing an FDA-approved treatment path.

If you are using a compounded product and its source checks out, nothing on this page tells you that you must switch. That decision belongs with you and your prescriber.

What this page will not do is use fear from a safety alert to push you into a provider before you know whether the alert applies. The next step is a fit check, not a panic purchase.

→ Get my personalized GLP-1 path Compare treatment paths by state, insurance, FDA-approved versus compounded preference, preferred form, and budget. No email needed to see your result.

Still not sure which GLP-1 program is right for you?

Take our free 60-second matching quiz. → Find My GLP-1 Path

It asks about your state, insurance, FDA-approved versus compounded preference, preferred treatment path, and budget — then shows you matches with source-verified pricing. No email needed to see your results.

Sources

All primary regulatory and first-party sources below were opened and reviewed for this version. Verified August 5, 2026.

• FDA Drug Alerts and Statements
• FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
• FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
• FDA requests removal of suicidal behavior and ideation warning from GLP-1 receptor agonist medications
• FDA counterfeit Ozempic rolling notice
• FDA Fullerton Wellness stop-use notice
• FDA compounded-semaglutide dosing-error alert
• FDA AEMS potential signals, October–December 2024
• FDA New Life Pharma warning letter 725661
• FDA ProRx warning letter 723704
• FDA Boothwyn Pharmacy warning letter 717525
• FDA GenoGenix warning letter 718739
• FDA Thrive Health Solutions warning letter 714891
• FDA Novo Nordisk adverse-event-reporting warning letter 717576
• FDA announcement: 30 telehealth-company warning letters
• FDA telehealth promotion guidance
• Federal Register: proposed 503B Bulks List determination
• Federal Register: comment-period extension
• Novo Nordisk December 2025 Wegovy recall statement
• openFDA Wegovy recall D-0245-2026
• openFDA Wegovy recall D-0393-2025
• openFDA Lupin liraglutide recall D-0541-2026
• Lupin FDA approval announcement
• FDA MedWatch
• FDA Warning Letters database
• FDA Drug Recalls

This page is editorial research, not medical advice. It has not been reviewed by a clinician. Nothing here should replace guidance from your prescriber or pharmacist. If you are having severe or worsening symptoms, seek medical care immediately.

Last verified: August 5, 2026 · Next scheduled full re-verification: September 2026